Pregnancy and Infant Outcomes Remain Unchanged With Multiple Sclerosis Therapy Ocrelizumab
In the largest data set of pregnancy outcomes for an anti-CD20 therapy in patients with multiple sclerosis (MS), results showed that in utero exposure to ocrelizumab (Ocrevus; Genentech) did not increase the risk of adverse pregnancy or infant outcomes. …